Epidemiological data indicate that approximately 13 million new cases of acute kidney injury (AKI) are reported worldwide each year, with nearly 50% directly attributable to Renal ischemiareperfusion injury (RIRI)(KDIGO, 2023) [3].RIRI not only serves as a major contributing factor to AKI but can also progress to chronic kidney disease (CKD), posing a significant threat to patient survival and long-term prognosis [4, 5]

The invention also relates to novel uses and methods of treatments using the aforementioned salts and/or compositions, in particular, with respect to the treatment of disturbances connected with either nitric oxide (NO) formation or impaired NO-system functions, in particular, hypertension, angina, impotence, circulatory and septic shock, stroke, inflammation, respiratory distress syndrome, adhesion and aggregation of platelets and leukocytes, endothelial dysfunction, gastrointestinal lesions, peristalsis disturbances, diabetes, pancreatitis, hypotension and Parkinson's disease
Canadians seeking access before this date will need to explore alternative pathways such as clinical trial participation or research peptide suppliers
S., Cali, A